Cell injection could replace corneal transplants for blurry vision
NCT ID NCT07711561
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This Phase 1 trial tests a new cell injection therapy called SNEC-I for people with mild to moderate corneal endothelial dysfunction or bullous keratopathy. The treatment uses non-cultured human corneal endothelial cells injected directly into the eye to restore the inner layer of the cornea. The study aims to assess safety and whether it can improve vision without the need for a full corneal transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a simple non-cultured endothelial cell injection (SNEC-I) using human corneal endothelial cells
- What this could lead to
- If successful, this approach could offer a less invasive alternative to corneal transplant for people with corneal endothelial dysfunction.
- What could go wrong
- This is an early Phase 1 trial with only 20 participants, so safety and effectiveness are not yet established. The treatment may not improve vision or could cause complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS KERATOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
L V Prasad Eye Institute
RECRUITINGHyderabad, Telangana, 500034, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.